How can hereditary hemochromatosis be differentiated from mimicking conditions such as megaloblastic anemia, pernicious anemia, and myelodysplastic syndrome?

Differentiating Hemochromatosis from Megaloblastic Anemia, Pernicious Anemia, and MDS

The key to distinguishing hereditary hemochromatosis from these mimics is the combination of elevated transferrin saturation (>55%) with elevated ferritin (>200 µg/mL in women, >300 µg/mL in men), followed by HFE genetic testing showing C282Y homozygosity in ~90% of cases 1.

Diagnostic Algorithm

Step 1: Initial Iron Studies Pattern

Hemochromatosis presents with:

• Transferrin saturation >55% (the most specific marker) 1
• Elevated ferritin (>200 µg/mL women, >300 µg/mL men) 1
• Normal or elevated hemoglobin (polycythemia occurs in 27.6% of cases) 2
• Both markers elevated together is the hallmark

Megaloblastic/Pernicious Anemia presents with:

• Low-normal or decreased transferrin saturation
• Normal to decreased ferritin (iron stores often depleted)
• Macrocytic anemia with low reticulocyte count 3
• MCV typically >100 fL

MDS presents with:

• Variable iron parameters (can show increased ferritin from transfusions)
• Macrocytic anemia with low reticulocytes 3
• Often pancytopenia, not just anemia

Step 2: Complete Blood Count Pattern

Hemochromatosis:

• Hemoglobin usually normal or elevated (anemia only in 10.8% of cases, typically from comorbidities) 2
• Normal cell counts unless advanced cirrhosis develops

Megaloblastic/Pernicious Anemia:

• Macrocytic anemia (MCV >100 fL)
• May have thrombocytopenia and/or leukopenia in severe cases 4
• Hypersegmented neutrophils on smear

MDS:

• Cytopenias (often multiple lineages)
• Macrocytic anemia common
• Monocytosis may be present 5

Step 3: Confirmatory Testing

For Hemochromatosis:

• HFE genetic testing: C282Y homozygosity in ~90% of cases 1
• H63D mutations have uncertain clinical significance 1
• Liver biopsy rarely needed with genetic testing available 1

For Megaloblastic/Pernicious Anemia:

• Vitamin B12 level (low)
• Anti-intrinsic factor antibodies (diagnostic for pernicious anemia) 5
• Methylmalonic acid and homocysteine (elevated)
• Responds to B12 replacement 5, 6

For MDS:

• Bone marrow biopsy showing dysplastic changes in ≥10% of cells 4
• Cytogenetic abnormalities (present in many cases) 5
• Ring sideroblasts may be present (29% of cases) 4
• WT1 mRNA expression may help distinguish from megaloblastic anemia 6

Critical Differentiating Features

Transferrin Saturation is Key

The transferrin saturation >55% is the single most important discriminator for hemochromatosis 1. Megaloblastic anemia and MDS typically show normal or low transferrin saturation despite potentially elevated ferritin from transfusions or inflammation.

Response to Treatment

• Hemochromatosis: Requires phlebotomy; does not respond to vitamins
• Megaloblastic/Pernicious anemia: Dramatic response to B12 replacement within weeks, with resolution of macrocytosis 5, 6
• MDS: No response to vitamins; progressive despite treatment 5, 6

Important Clinical Pitfalls

Rare Concurrent Presentations

While generally considered mutually exclusive diagnoses, rare cases of concurrent hemochromatosis with pernicious anemia 7, 8 or MDS 9, 10 have been reported. Key points:

• Pernicious anemia may mask hemochromatosis by preventing iron absorption through atrophic gastritis 8
• When both present, iron overload is typically less severe and responds rapidly to phlebotomy 7
• HFE mutations occur with increased frequency in MDS patients (48% in one study vs. general population) 9
• If macrocytosis persists after B12 replacement, consider underlying MDS 5, 6

Ferritin Confounders

Ferritin elevation alone is not specific for hemochromatosis 11. Ferritin rises with:

• Inflammation (acute phase reactant)
• Fatty liver disease/metabolic syndrome
• Alcohol consumption
• Cell necrosis
• Malignancy

Always interpret ferritin with transferrin saturation 1, 11.

Bone Marrow Findings Overlap

Bone marrow examination can show megaloblastic changes in both megaloblastic anemia and MDS, making histologic distinction difficult in ~45% of cases 4. The presence of clonal cytogenetic abnormalities definitively indicates MDS 5.

Morning Fasting Not Required

Blood samples for transferrin saturation should be drawn in the morning, but fasting does not improve diagnostic utility 11.